论文部分内容阅读
近年来肺癌的发病率呈逐年升高趋势,且肺癌死亡率在我国居恶性肿瘤死亡率的第1位.肺癌中非小细胞肺癌(NSCLC)占80%左右,其中早期NSCLC仅占20%~30%,治疗方式均以手术治疗为主.晚期NSCLC主要采取化学治疗方法,但化学治疗药物的不良反应限制了它在临床上的广泛应用.靶向药物较传统化学治疗药物疗效确切、不良反应轻、给药便利,已成为NSCLC治疗过程中不可或缺的重要手段.本研究就靶向药物治疗NSCLC的研究
In recent years, the incidence of lung cancer showed an increasing trend year by year, and the death rate of lung cancer ranks the first in China. The incidence of non-small cell lung cancer (NSCLC) is about 80% in lung cancer, of which only 20% 30% of the treatment are based on surgical treatment of advanced NSCLC mainly to take chemotherapy, but the adverse effects of chemotherapy drugs limits its widespread clinical application of targeted drugs than traditional chemotherapy drugs curative effect, adverse reactions Light, convenient administration, has become an indispensable and important method in the treatment of NSCLC.In this study, targeted drug treatment of NSCLC